Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will investigate how the levels of a repeat dose of CTAP101 changes in the body
over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances
(pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency
and secondary hyperparathyroidism (SHPT).